HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akahori, H. Articles by Miyazaki, H. Search for Related Content PubMed PubMed Citation Articles by Akahori, H. Articles by Miyazaki, H.

Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor on Thrombocytopenia Induced by a New Myelosuppressive Chemotherapy Regimen in Mice

Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, Gunma, Japan

Key Words. Thrombopoietin • Megakaryocyte growth and development factor (MGDF) • Chemotherapy • Thrombocytopenia • Platelet • Neutropenia

Dr. Hiromichi Akahori, Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., 3 Miyahara-cho, Takasaki, Gunma 370-12, Japan.

Thrombopoietin, the endogenous c-Mpl ligand, is a novel lineage-specific hematopoietic factor that plays a pivotal role in the regulation of megakaryocytopoiesis and thrombopoiesis. In this study, we examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated molecule of recombinant human c-mpl ligand derivatized with polyethylene glycol, on myelosuppressive chemotherapy-induced thrombocytopenia in mice. We developed a new murine model of thrombocytopenia induced by I.V. injections of mitomycin C (MMC) for two consecutive days. In control mice, platelet counts began to decrease on day 6, reached a nadir of less than 5% of basal level on day 14, and could not recover to basal level by day 26. Administration of PEG-rHuMGDF greatly enhanced recovery of the number of megakaryocyte progenitor cells and the megakaryocytes in bone marrow, and markedly reduced the severity of thrombocytopenia; it also accelerated platelet recovery in a dose-dependent manner in myelosuppressed mice. Mice receiving consecutive administration of higher doses of PEG-rHuMGDF showed no thrombocytopenia but rather had platelet counts being increased over basal level. Although absolute neutrophil counts and red cell counts also were decreased following MMC treatment, administration of PEG-rHuMGDF also improved neutropenia and anemia. Administration of PEG-rHuMGDF on alternate days or once a week after chemotherapy was almost as effective as consecutive administration in improving thrombocytopenia. Combined administration of PEG-rHuMGDF and rHuG-CSF had an addictive effect on improvement of thrombocytopenia and neutropenia. These results suggest that PEG-rHuMGDF is a therapeutically effective agent in the treatment of thrombocytopenia associated with chemotherapy.

This article has been cited by other articles:

				C. H. Moskowitz, P. A. Hamlin, J. Gabrilove, J. R. Bertino, C. S. Portlock, D. J. Straus, A. N. Gencarelli, S. D. Nimer, and A. D. Zelenetz Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Ann. Onc., November 1, 2007; 18(11): 1842 - 1850. [Abstract] [Full Text] [PDF]

				B. Zhou, X. Kong, and D. I. H. Linzer Enhanced Recovery from Thrombocytopenia and Neutropenia in Mice Constitutively Expressing a Placental Hematopoietic Cytokine Endocrinology, January 1, 2005; 146(1): 64 - 70. [Abstract] [Full Text] [PDF]

				A. M. Farese, T. J. MacVittie, L. Roskos, and R. B. Stead Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG-rHuMGDF Stem Cells, January 1, 2003; 21(1): 79 - 89. [Abstract] [Full Text] [PDF]

				S. Bhattacharyya, J. Lin, and D. I. H. Linzer Reactivation of a Hematopoietic Endocrine Program of Pregnancy Contributes to Recovery from Thrombocytopenia Mol. Endocrinol., June 1, 2002; 16(6): 1386 - 1393. [Abstract] [Full Text] [PDF]

				M. de Serres, R. L. Yeager, J. E. Dillberger, G. Lalonde, G. H. Gardner, C. A. Rubens, A. H. Simkins, J. M. Sailstad, M. J. McNulty, and J. L. Woolley Pharmacokinetics and Hematological Effects of the PEGylated Thrombopoietin Peptide Mimetic GW395058 in Rats and Monkeys After Intravenous or Subcutaneous Administration Stem Cells, November 1, 1999; 17(6): 316 - 326. [Abstract] [Full Text]

				M. De Serres, B. Ellis, J. E. Dillberger, S. K. Rudolph, J. T. Hutchins, C. M. Boytos, D. L. Weigl, and R. B. DePrince Immunogenicity of Thrombopoietin Mimetic Peptide GW395058 in BALB/c Mice and New Zealand White Rabbits: Evaluation of the Potential for Thrombopoietin Neutralizing Antibody Production in Man Stem Cells, July 1, 1999; 17(4): 203 - 209. [Abstract] [Full Text]

				T. Kato, A. Matsumoto, K. Ogami, T. Tahara, H. Morita, and H. Miyazaki Native Thrombopoietin: Structure and Function Stem Cells, September 1, 1998; 16(5): 322 - 328. [Abstract] [Full Text]

				K. Shibuya, H. Akahori, K. Takahashi, E. Tahara, T. Kato, and H. Miyazaki Multilineage Hematopoietic Recovery by a Single Injection of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Myelosuppressed Mice Blood, January 1, 1998; 91(1): 37 - 45. [Abstract] [Full Text] [PDF]